Global Edema Pipeline H2 2015 Review Research Report

Oct 15, 2015, 06:00 ET from Life Science Industry Research

PUNE, India, October 15, 2015 /PRNewswire/ --

New market research titled Edema - Pipeline Review, H2 2015 is a report providing data and information that helps strengthen Edema R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Edema pipeline spread across 44 pages, analyzing 3 companies, 5 drug profiles and supported with 19 tables and 14 figures is now available at http://www.lifescienceindustryresearch.com/edema-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Edema and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in this Edema pipeline H2 2015 review report include Apeptico Forschung und Entwicklung GmbH, Mirrx Therapeutics A/S and Otsuka Holdings Co., Ltd. Drug profiles discussed in this report are AP-301, BC-1215, CD-52, pentosan polysulfate sodium, Synthetic Peptides for Edema and tolvaptan. Order a copy of Edema - Pipeline Review, H2 2015 market research report at http://www.lifescienceindustryresearch.com/purchase?rname=59643 .

The report provides a snapshot of the global therapeutic landscape of Edema and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Edema and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Edema pipeline on the basis of target, MoA, route of administration and molecule type, latest news and deals relating related to pipeline products.

Another newly published market research titled EpiCast Report: Sepsis - Epidemiology Forecast to 2023 is a report that provides an overview of the risk factors and global trends of sepsis in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast for the diagnosed incident cases of sepsis segmented by sex, age, severity stage, and causative organism; a 10-year epidemiology forecast for the sepsis mortality cases segmented by sex, age, severity stage, and causative organism. Additionally, the report provides a 10-year epidemiological forecast for the diagnosed incident cases of sepsis that have comorbid conditions disseminated intravascular coagulopathy (DIC), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), and acute kidney injury (AKI) in the 6MM. Global estimates for the year 2013 showed that there are around 20 to 30 million patients affected by sepsis every year, of which around 8 million patients die (Reinhart et al., 2013). In the 6MM, the diagnosed incident cases of sepsis will grow from 1,060,052 cases in 2013 to 1,129,816 cases in 2023, at an Annual Growth Rate (AGR) of 0.66% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of sepsis in the 6MM. the sepsis mortality cases will increase from 439,015 cases in 2013 to 531,282 cases in 2023, at an AGR of 2.10% from 2013 to 2023 in the 6MM. This report of 65 pages is available at http://www.lifescienceindustryresearch.com/epicast-report-sepsis-epidemiology-forecast-to-2023.html .

Explore more reports on Pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us:   

LifeScienceIndustryResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@lifescienceindustryresearch.com

Connect with Us:  

G+ / Google Plus: https://plus.google.com/112612135957880308475/about

Twitter: https://twitter.com/LifeSciReports

RSS / Feeds: http://www.lifescienceindustryresearch.com/feed/

SOURCE Life Science Industry Research